Sébastien Wälchli is group leader at the Translational Research Unit, Dept. for Cellular therapy, Oslo University Hospital) a newly established pre-clinical entity directly connected to the immunomonitoring unit. He leads the molecular biology of the T-cell receptor (TCR) and the Chimeric Antigen Receptor (CAR) development platforms. The TCR platform has led to the filing of numerous patents, the establishment of a biotech (Zelluna Immuntherapy AS, 2016) and the first TCR tested in human in Norway (ClinicalTrials.gov Identifier: NCT03431311). The CAR platform has completed the pre-clinical development of 2 candidates (CD37CAR: and OSCAR) and is working on around 15 new constructs, most of them directed against solid tumours. In addition, the lab is developing innovative solution for cellular therapy, such as advanced universal therapeutic solutions (NK-TCR, TCR-CAR), and different innovative tools in the immunotherapeutic field (vaccination, effector cell improvement, etc.).